Abatacept (CTLA4Ig) for rheumatoid arthritis unresponsive to current therapies - horizon scanning review
NHSC
Record ID 32004000896
English
Authors' objectives:
This study aims to summarise the currently available evidence on abatacept (CTLA4Ig) for rheumatoid arthritis unresponsive to current therapies.
Authors' recommendations:
Abatacept (CTLA4Ig, BMS-188667) is a fusion protein and is the first in a new class of selective co-stimulatory modulators that inhibit T-cell proliferation. Abatacept is in phase III clinical trials for people with rheumatoid arthritis (RA) who are unresponsive to current therapies. In phase II trials abatacept with methotrexate increased overall response rates regardless of disease duration, increased remissions, and improved quality of life; with etanercept abatacept increased response rates and quality of life; and as monotherapy increased response rates.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antirheumatic Agents
- Arthritis, Rheumatoid
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.